Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 11 | 2025 | 242 | 1.880 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 118 | 1.550 |
Why?
|
| Oncologists | 3 | 2021 | 43 | 1.420 |
Why?
|
| Ovarian Neoplasms | 6 | 2022 | 826 | 1.250 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1536 | 0.790 |
Why?
|
| Abortion, Legal | 1 | 2023 | 30 | 0.790 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 97 | 0.780 |
Why?
|
| Cancer Survivors | 2 | 2022 | 108 | 0.670 |
Why?
|
| Drug Costs | 1 | 2021 | 66 | 0.640 |
Why?
|
| Abortion, Induced | 1 | 2023 | 168 | 0.630 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 523 | 0.550 |
Why?
|
| Telemedicine | 1 | 2021 | 250 | 0.520 |
Why?
|
| Carcinoma, Endometrioid | 3 | 2025 | 60 | 0.500 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 1211 | 0.420 |
Why?
|
| Pandemics | 5 | 2022 | 913 | 0.390 |
Why?
|
| Female | 28 | 2025 | 51463 | 0.350 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 2037 | 0.330 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 31 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2658 | 0.320 |
Why?
|
| Humans | 33 | 2025 | 97893 | 0.290 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 289 | 0.290 |
Why?
|
| Endometrial Hyperplasia | 2 | 2022 | 12 | 0.290 |
Why?
|
| Quality of Life | 3 | 2022 | 1891 | 0.290 |
Why?
|
| Palliative Care | 2 | 2021 | 289 | 0.270 |
Why?
|
| Aged | 16 | 2025 | 21701 | 0.240 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 7386 | 0.240 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 165 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 2080 | 0.200 |
Why?
|
| Neoplasms | 3 | 2024 | 3340 | 0.190 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 1103 | 0.190 |
Why?
|
| Electronics | 1 | 2022 | 21 | 0.190 |
Why?
|
| Mental Health | 2 | 2021 | 219 | 0.180 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 661 | 0.170 |
Why?
|
| Morbidity | 1 | 2022 | 162 | 0.170 |
Why?
|
| Frailty | 1 | 2023 | 103 | 0.170 |
Why?
|
| Decision Trees | 1 | 2021 | 63 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.170 |
Why?
|
| Middle Aged | 15 | 2025 | 29352 | 0.170 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 68 | 0.160 |
Why?
|
| Markov Chains | 1 | 2021 | 146 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 60 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 112 | 0.160 |
Why?
|
| Quinolines | 1 | 2021 | 97 | 0.160 |
Why?
|
| Hysterectomy | 3 | 2019 | 174 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2021 | 77 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 166 | 0.160 |
Why?
|
| Chicago | 3 | 2020 | 1513 | 0.160 |
Why?
|
| Carboplatin | 1 | 2021 | 331 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 195 | 0.150 |
Why?
|
| Depression | 2 | 2021 | 616 | 0.150 |
Why?
|
| Paclitaxel | 1 | 2021 | 483 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 336 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2020 | 417 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 473 | 0.140 |
Why?
|
| Adult | 12 | 2025 | 29453 | 0.140 |
Why?
|
| Health Resources | 1 | 2018 | 80 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 311 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1283 | 0.130 |
Why?
|
| Communication | 1 | 2021 | 455 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 1098 | 0.130 |
Why?
|
| Health Equity | 1 | 2020 | 116 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2021 | 383 | 0.130 |
Why?
|
| Self Care | 1 | 2018 | 188 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 478 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 580 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 92 | 0.120 |
Why?
|
| Pregnancy | 1 | 2023 | 3246 | 0.120 |
Why?
|
| Corneal Injuries | 1 | 2015 | 8 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10947 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 323 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 341 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 176 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 525 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 539 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 403 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1089 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2015 | 340 | 0.090 |
Why?
|
| Prostatectomy | 1 | 2015 | 490 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1060 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2012 | 160 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 4112 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2012 | 411 | 0.080 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 337 | 0.080 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 105 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 324 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 1009 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 321 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 665 | 0.070 |
Why?
|
| Anxiety | 2 | 2021 | 370 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2680 | 0.060 |
Why?
|
| Young Adult | 5 | 2021 | 7504 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 1193 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2373 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1764 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1105 | 0.060 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 130 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 920 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 10078 | 0.050 |
Why?
|
| Geographic Information Systems | 1 | 2024 | 29 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1995 | 0.050 |
Why?
|
| Incidence | 2 | 2021 | 1776 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2007 | 1527 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 6224 | 0.050 |
Why?
|
| United States | 3 | 2021 | 8183 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 3202 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1960 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 193 | 0.040 |
Why?
|
| Rural Health Services | 1 | 2021 | 16 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 249 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 9682 | 0.040 |
Why?
|
| Rural Population | 1 | 2021 | 191 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 902 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 211 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 406 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 1120 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 139 | 0.040 |
Why?
|
| Social Class | 1 | 2020 | 156 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 23 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 323 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 238 | 0.030 |
Why?
|
| Urban Population | 1 | 2018 | 246 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 214 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 601 | 0.030 |
Why?
|
| Endometrium | 1 | 2015 | 51 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 70 | 0.030 |
Why?
|
| Sexuality | 1 | 2015 | 40 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 218 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 207 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 422 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 355 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 428 | 0.020 |
Why?
|
| Robotics | 1 | 2015 | 271 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2012 | 231 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1273 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2012 | 139 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 411 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 674 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1567 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 356 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2555 | 0.020 |
Why?
|
| Child | 1 | 2021 | 7680 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1790 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2015 | 791 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1836 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 5555 | 0.010 |
Why?
|
| Male | 1 | 2015 | 46995 | 0.010 |
Why?
|